Jean François Brochard

Many stakeholders discussed yesterday in #Brussels the importance of the EU’s global competitiveness for Europeans living with rare diseases. Caroline Ven , CEO of #pharmabe, stressed that competitiveness is key. pharma.be’s memorandum for the 2024 national elections is entitled “For a healthy Belgium”. Healthy in terms of both its citizens and the economy of the country. Caroline Ven: “To secure future #competitiveness of the #EU, three cornerstones need to be in place: increased fundamental R&D the right conditions for entrepreneurship and performant national #healthcare systems, including sufficient budgets for innovative treatments including for rare diseases.”. “For example, only 53% of the 19 orphan dossiers, including advanced therapy medicinal products ( #ATMPs), analysed in 2023 by the Belgian Commission of Reimbursement led to reimbursement.”. In addition, she focussed on the many Unmet Medical Needs still existing. Industry has the addressing of #UMNs at its very core. But sometimes it takes huge efforts, e.g., $ 42 billion has already been spent on clinical trials for Alzheimer’s diseases, without a cure being available yet. At the same time, it is not just about breakthrough #innovation, room for incremental innovation is absolutely crucial: this is true across industries. The return on investments, also in R&D for rare diseases, is essential to ensure the virtuous cycle of biopharmaceutical R&D: current earnings are invested in the treatments of the future. #GlobalCounsel EURORDIS-Rare Diseases Europe @Radiorg Eva Schoeters EFPIA - European Federation of Pharmaceutical Industries and Associations EUCOPE - European Confederation of Pharmaceutical Entrepreneurs EuropaBio - the European Association for Bioindustries UCB Novo Nordisk Sanofi Belgique Takeda in Belgium #rarediseases #orphandrugs #Belgium Emma Eatwell Stefan Joris Alexander Natz Daria Julkowska

103

1 commentaire

France: The Pharma-Place-to-Be in 2024! 🌟 Exciting developments are happening in the pharmaceutical world, and France is at the forefront of it all. According to Fierce Pharma, major investments are pouring into R&D and manufacturing in the EU, with France taking a leading role. Sanofi is investing $1.1B in treatments for COPD, Asthma, MS, and T1D, along with over $100M to boost Dupixent and an additional $10M+ for TZIELD. AstraZeneca is committing nearly $400M to its initiatives. Pfizer plans to spend over $500M on R&D in the next five years. These are just a few examples, with other significant investments coming from AbbVie, Novartis, Kenvue, and Chiesi Group. What's particularly intriguing is the dynamic shift we're witnessing: while the EU, particularly France, is becoming a hub for R&D and manufacturing, US companies are focusing on direct-to-patient initiatives. This includes direct contracts with pharmacies, diagnostics, and telehealth providers. 🔄 Produce and Innovate in Europe, Sell in the US 🔄 The future of pharma looks promising with this transatlantic synergy! For more insights, check out the full article from Fierce Pharma: https://lnkd.in/dQ9rB6ks

7

Yes, the CIR costs €7+ billion, but this is an investment, not a burden. It fuels technological breakthroughs, supports critical industries, and ensures France remains competitive on the global stage. Attacking this fiscal pillar is a dangerous gamble that risks driving research talent and investments abroad, jeopardizing our sovereignty and industrial future. Having supported many companies, setting up their R&D in France and having led Healthtech start-ups, I know how key this is. Let's not harm a competitive advantage!! #innovation #frenchsovereignty #researchtaxcredit #CIR #economicindependence #competitiveness #biotech #medtech #healthech

9

🔬 𝗡𝗲𝘄 𝗔𝗱𝘃𝗮𝗻𝗰𝗲 𝗶𝗻 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗻𝗴 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝘁𝗼 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗰𝗳𝗗𝗡𝗔! 💡   A recent study shows that analyzing circulating cell-free DNA (cfDNA) fragmentome can predict early response to immunotherapy, regardless of cancer type or treatment. 💪 Thanks to the 𝗕𝗶𝗮𝗯𝗼𝗼𝘀𝘁𝗲𝗿 technology, which identifies specific profiles of circulating DNA fragment sizes, fragments longer than 1,650 base pairs have been identified as a key predictive marker. 🧬   📈 Patients with a higher proportion of these fragments have improved progression-free survival, paving the way for more personalized monitoring and treatment optimization.   Find the full interview with Professor SALAS at ESMO 2024: https://lnkd.in/eufJ7Ryh (English Subtitles available)   ID SOLUTIONS, exclusive partner and distributor of ADELIS Technologies' solutions.   #Immunotherapy #Cancer #cfDNA #Innovation #PersonalizedMedicine

5